Antibody-Drug Conjugate Active in Resistant Lung Cancer

Antibody-Drug Conjugate Active in Resistant Lung Cancer

An antibody-drug conjugate (ADC) focusing on the HER3 boost part receptor had indispensable scientific project in EGFR inhibitor-resistant non-puny cell lung most cancers (NSCLC), a preliminary scientific trial showed. Patritumab deruxtecan (HER3-DXd) led to purpose responses in 22 of 57…